Dr William Parker
MA, MB, BChir, PhD, PGCertTLHE, DHMSA, MRCS, MRCP
Clinical Medicine, School of Medicine and Population Health
NIHR Clinical Lecturer in Cardiology
+44 114 226 6159
Full contact details
Clinical Medicine, School of Medicine and Population Health
The Cardiovascular Research Unit (CVRU), Centre for Biomedical Research,
Northern General Hospital
Herries Road
Sheffield
S5 7AU
- Profile
-
For enquiries please contact - SMPH-West-Operational@sheffield.ac.uk
I studied Medicine and Pharmacology at the University of Cambridge before returning to my home city of Sheffield to complete the Academic Foundation and Core Medical Training Programmes.
I obtained Membership of the Royal College of Surgeons of England in 2013 and of the Royal Colleges of Physicians of the United Kingdom in 2014.
In 2015, I was appointed Clinical Research Fellow in Cardiology at the University of Sheffield with clinical tenure at the South Yorkshire Cardiothoracic Centre, Northern General Hospital.
In 2018, I was awarded a three-year British Heart Foundation Clinical Training Fellowship completed a PhD under the primary supervision of Professor Rob Storey.
In January 2022, I became National Institute of Health and Care Research (NIHR) Clinical Lecturer in Cardiology. I hold a National Training Number in Cardiology and am Honorary Registrar at the South Yorkshire Cardiothoracic Centre.
Distinctions include a high commendation from the International Aspirin Foundation in 2021, and being ranked the top candidate in the UK at national selection for the cardiology training programme.
- Research interests
-
My main research interest is in improving the quality and safety of drugs used to treat and prevent cardiovascular disease, especially anti-thrombotic therapy for ischaemic heart disease.
Specifically, I am currently investigating the dose-dependent effects of aspirin when used in combination with other antithrombotic agents and how drug regimens can be optimised to augment benefits whilst reducing harm.
I have a wider clinical and academic interest in the pharmacological management of cardiovascular disease and how this can be improved and investigated.
I also study and research the history of medicine and completed the Diploma in the History of Medicine of the Society of Apothecaries of London in 2019, receiving the Maccabean Prize and Osler Lectureship.
Current Projects:
- The WILLOW programme: a series of randomised controlled trials investigating the dose-dependent effects of aspirin in combination with other antithrombotic drugs).
- Laboratory research into aspirin preparations, metabolism of aspirin and aspirin’s effects on the thromboinflammatory response.
- Co-investigator on a wide range of local and multi-centre clinical trials within the Cardiovascular Research Unit.
- Research into the history of cardiology and cardiac surgery, particularly early use of cardiopulmonary bypass.
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Combining DAPT with a PPI faces the acid test of real-world use. European Heart Journal, 40(24), 1971-1974.
- Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets, 30(2), 148-157. View this article in WRRO
- Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets, 30(5), 579-588.
- Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI). Circulation, 138(13), 1290-1300. View this article in WRRO
- Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study). Thrombosis and Haemostasis, 118(07), 1250-1256. View this article in WRRO
- Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thrombosis and Haemostasis, 117(06), 1093-1100.
- Ticagrelor: agonising over its mechanisms of action. Blood, 128(23), 2595-2597.
- Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus. Circulation, 134(11), 793-796. View this article in WRRO
- Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. Heart, 102(10), 783-789.
- International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature. Pharmacological Reviews, 61(1), 1-8.
- Choosing a perspective on mortality with DAPT. European Heart Journal, ehv610-ehv610.
Chapters
All publications
Journal articles
- Detection of chronic obstructive pulmonary disease and frequency of cardiopulmonary events in patients with a significant smoking history hospitalised for acute myocardial infarction. European Heart Journal, 45(Supplement_1).
- Drug therapies for stroke prevention. British Journal of Cardiology.
- Interactions between aspirin and ticagrelor during experimental human endotoxaemia. European Heart Journal, 44(Supplement_2).
- Coagulation disorders and thrombotic complications in heart failure with preserved ejection fraction. Current Problems in Cardiology, 102127-102127.
- The first mitral valve replacement?. The Annals of Thoracic Surgery.
- Thrombotic Coronary Occlusion and Reperfusion: Unraveling the Determinants. Journal of the American College of Cardiology, 81(19), 1933-1936.
- Platelets in 2023: hellos and goodbyes. Platelets, 34(1).
- Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes. Vascular Pharmacology, 149, 107145-107145.
- Blood coagulation disorders in heart failure: from basic science to clinical perspectives. Journal of Cardiac Failure.
- Treatment inequity in antiplatelet therapy for ischaemic heart disease in patients with advanced chronic kidney disease: releasing the evidence vacuum. Platelets, 34(1).
- Oral Presentation No. 84 Initial clinical experience with 6-hour enoxaparin regimen in opiate-treated patients undergoing primary percutaneous coronary intervention. Cardiovascular Research, 118(Supplement_2).
- Illustrated state-of-the-art capsules of the ISTH 2022 congress. Research and Practice in Thrombosis and Haemostasis, 6(5). View this article in WRRO
- Platelets and open access - a new era dawns.. Platelets, 1-2.
- THROMBOINFLAMMATORY RESPONSE TO ON-PUMP CORONARY ARTERY BYPASS GRAFT SURGERY LEADS TO IMPAIRED PLATELET REACTIVITY IN PATIENTS WITH ACUTE CORONARY SYNDROME. Journal of the American College of Cardiology, 79(9), 1094-1094.
- Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nature Reviews Cardiology.
- A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes : role of dosing and glycaemic control. Cardiovascular Diabetology, 20(1).
- Ticagrelor monotherapy in CKD: better safety at what price?. Eur Heart J.
- Ticagrelor : clinical development and future potential. Reviews in Cardiovascular Medicine, 22(2), 373-394. View this article in WRRO
- Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy.. Platelets, 1-7.
- Coagulopathy and sepsis: Pathophysiology, clinical manifestations and treatment. Blood Reviews, 100864-100864.
- Thrombotic complications in patients with COVID-19 : pathophysiological mechanisms, diagnosis, and treatment. Cardiovascular Drugs and Therapy, 35(2), 215-229.
- Platelets and the endothelium: active participants in severe COVID-19 infection. JACC: Basic to Translational Science, 6(3), 219-221.
- Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention : a GLOBAL LEADERS substudy. Platelets. View this article in WRRO
- Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease. European Heart Journal Supplements, 22(Supplement_M), M26-M34.
- Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus : a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels. Cardiovascular Diabetology, 19(1). View this article in WRRO
- Acoustic shock: an update review. The Journal of Laryngology & Otology, 134(10), 848-853.
- 51 Adherence to cardiologist recommendations regarding extended duration of ticagrelor for patients undergoing PCI for myocardial infarction. Heart, 106(Suppl 2), a41-a41.
- Glimpsing Into the miRe of Ischemia Reperfusion Injury. Transplantation, 104(9), 1769-1771.
- Pharmacology and potential role of selatogrel, a subcutaneous platelet P2Y12 receptor antagonist. Expert Opinion on Emerging Drugs. View this article in WRRO
- Opiates and Clopidogrel Efficacy. Journal of the American College of Cardiology, 75(3), 301-303.
- Comparison of Contemporary Drug-eluting Coronary Stents – Is Any Stent Better than the Others?. Heart International, 14(1), 34-34.
- Combining DAPT with a PPI faces the acid test of real-world use. European Heart Journal, 40(24), 1971-1974.
- Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets, 30(2), 148-157. View this article in WRRO
- Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. Platelets, 30(5), 579-588.
- Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI). Circulation, 138(13), 1290-1300. View this article in WRRO
- Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study). Thrombosis and Haemostasis, 118(07), 1250-1256. View this article in WRRO
- Secondhand Hypertrophy. Transplantation, 102(9), e397-e398.
- Dual antiplatelet therapy in the ‘real world’. Heart, 104(19), 1555-1556.
- Long-term treatment-related morbidity in differentiated thyroid cancer: a systematic review of the literature. Pragmatic and Observational Research, 8, 57-67. View this article in WRRO
- Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thrombosis and Haemostasis, 117(06), 1093-1100.
- Ticagrelor: agonising over its mechanisms of action. Blood, 128(23), 2595-2597.
- Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus. Circulation, 134(11), 793-796. View this article in WRRO
- Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. Heart, 102(10), 783-789.
- ‘Acoustic shock’: A new occupational disease? Observations from clinical and medico-legal practice. International Journal of Audiology, 53(10), 764-769.
- Cystic swellings of the neck. Surgery (Oxford), 27(12), 530-534.
- International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature. Pharmacological Reviews, 61(1), 1-8.
- Oral anticoagulation and non-steroidal anti-inflammatory drugs: a recipe for bleeding. European Heart Journal.
- The life and work of Judson T. Chesterman, pioneering cardiac surgeon. Journal of Medical Biography.
- THE ROLE OF PLATELET P2Y12 IN INFLAMMATION. British Journal of Pharmacology.
- Aspirin dosing for atherosclerotic cardiovascular disease: should we be more ADAPTABLE?. Cardiovascular Research.
- Anticoagulation therapy in non-valvular atrial fibrillation in the COVID-19 era: is it time to reconsider our therapeutic strategy?. European Journal of Preventive Cardiology.
- Antithrombotic therapy for patients with chronic coronary syndromes. Heart.
- Aspirin after PCI: in the twilight of its years?. Platelets, 1-3.
- Benefits and Challenges of Robotic Pelvic Surgery in a Cardiac Transplant Recipient. Surgical Innovation, 155335062093600-155335062093600.
- Novel approaches to P2Y12 inhibition and aspirin dosing. Platelets, 1-8.
- Offset of ticagrelor prior to coronary artery bypass graft surgery for acute coronary syndromes: effects on platelet function and cellular adenosine uptake. Platelets, 1-7.
- Choosing a perspective on mortality with DAPT. European Heart Journal, ehv610-ehv610.
- Prolonged enoxaparin therapy compared with standard-of-care antithrombotic therapy in opiate-treated patients undergoing primary percutaneous coronary intervention. Platelets. View this article in WRRO
- New Antithrombotic Drugs in Acute Coronary Syndrome. Journal of Clinical Medicine, 9(7), 2059-2059.
- Computed tomography chest imaging offers no advantage over chest X-ray in the initial assessment of gestational trophoblastic neoplasia. British Journal of Cancer.
Chapters
- Antithrombotic therapy in ST-elevation acute myocardial infarction and non-ST elevation acute coronary syndromes In De Caterina R, Moliterno DJ & Kristensen SD (Ed.), The ESC Textbook of Thrombosis (pp. 179-C16P154). Oxford University PressOxford
- Acute coronary syndromes: Thrombotic Response
Conference proceedings papers
- 71 Initial clinical experience with 6-hour enoxaparin regimen in opiate-treated patients undergoing primary percutaneous coronary intervention. Acute coronary syndromes & Interventional Cardiology
- 171 Prevalence of a nice-defined indication for inclisiran in a real-world trans-pandemic acute coronary syndrome cohort. Stable IHD/Prevention/Hypertension/Lipids
- P28 DOES MILD CORONARY ARTERY ATHEROSCLEROSIS PROGRESS AT SERIAL ANGIOGRAPHY?. Cardiovascular Research, Vol. 114(suppl_2) (pp S9-S9)
- Does deactivation of a site's surgical cardiac transplant program affect the long-term survival of its recipients?. EUROPEAN JOURNAL OF HEART FAILURE, Vol. 20 (pp 447-447)
- ULTRA-LOW-DOSE TWICE-DAILY ASPIRIN IMPROVES HEMOSTASIS AND MAINTAINS PLATELET INHIBITION IN ACUTE CORONARY SYNDROME PATIENTS RECEIVING TICAGRELOR. Journal of the American College of Cardiology, Vol. 71(11) (pp A30-A30)
- 72 Offset of ticagrelor prior to coronary artery bypass graft surgery (cabg) surgery. Heart, Vol. 103(Suppl 5) (pp A53.2-A54)
- Teaching interests
-
I am Deputy Co-ordinator of the Phase 1 Cardiovascular Module for the Sheffield MB ChB course and contribute to teaching of medical students from first to final years. I also lecture on the Masters in Cardiovascular Research and Masters in Genomic Medicine programmes. I routinely supervise students completing the BSc in Medical Research.
I was awarded the Postgraduate Certificate in Teaching and Learning for Higher Education from the School of Education at the University of Sheffield in 2021.
I am also passionate about public engagement and have recently devised and delivered sessions for the NHS 70th Anniversary celebrations, Sheffield Ignite Academy, Pecha Kucha foundation and the Millennium Galleries, Sheffield (Leonardo Da Vinci exhibition).
- Professional activities and memberships
-
I am Co-ordinator of the European Society of Cardiology Working Group on Thrombosis Young Researchers, having previously been a Nucleolus member (2018-20) and Vice Co-ordinator (2020-22).
I am incoming Co-Editor-in-Chief of the well-respected journal Platelets, having been a Principal Editor since 2020.
I am Deputy President of the Faculty of the History & Philosophy of Medicine & Pharmacy at the Worshipful Society of Apothecaries of London.
I am a member of the Archives Committee at the British Cardiovascular Society.